Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17049713 | 0.81 | KDM4E (0.36) | CRHR1KDM4EL3MBTL1MEN1LMNA | |
| SCHEMBL17049710 | 0.76 | KDM4E (0.39) | KDM4EL3MBTL1MEN1LMNAHPGD | |
| SCHEMBL17049714 | 0.74 | LMNA (0.36) | CRHR1KDM4EL3MBTL1MEN1LMNA | |
| SCHEMBL17049716 | 0.74 | GSTP1 (0.37) | KDM4EL3MBTL1NLRP3 | |
| SCHEMBL9889297 | 0.72 | CYP3A4 (0.35) | KDM4EL3MBTL1MEN1LMNAHPGD | |
| SCHEMBL27963241 | 0.72 | HPGD (0.41) | CRHR1KDM4EL3MBTL1MEN1LMNA | |
| SCHEMBL1035454 | 0.72 | KDM4E (0.34) | CRHR1KDM4EL3MBTL1MEN1LMNA | |
| SCHEMBL9889322 | 0.71 | CYP3A4 (0.34) | KDM4EL3MBTL1MEN1LMNAHPGD | |
| Propene SCHEMBL28249246 | 0.71 | CRHR1 (0.35) | CRHR1KDM4EL3MBTL1MEN1LMNA | |
| SCHEMBL1036934 | 0.71 | KDM4E (0.36) | CRHR1KDM4EL3MBTL1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451847-B1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | IGM GROUP B V (NL) | 2021-11-24 | — | — | EP | disclosed |
| US-9120900-B2 | Polymer-bound bisacylphosphine oxides | BASF SE (DE) | 2015-09-01 | — | — | US | disclosed |
| US-8883872-B2 | Polymer-bound bisacylphosphine oxides | BASF SE (DE) | 2014-11-11 | — | — | US | disclosed |
| US-20120142805-A1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | BASF SE (DE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142805-A1 | POLYMER-BOUND BISACYLPHOSPHINE OXIDES | PHOSPHO1, PARG, PEBP1 | CRHR1 4409/4885KDM4E 3616/4885L3MBTL1 1928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.